Research and Markets (http://www.researchandmarkets.com/research/dvpgvs/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Papillary Thyroid Cancer Overview
  3. Therapeutics Development
  4. Pipeline Products for Papillary Thyroid Cancer - Overview
  5. Pipeline Products for Papillary Thyroid Cancer - Comparative Analysis
  6. Papillary Thyroid Cancer - Therapeutics under Development by Companies
  7. Papillary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes
  8. Papillary Thyroid Cancer - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Papillary Thyroid Cancer - Products under Development by Companies
  13. Papillary Thyroid Cancer - Products under Investigation by Universities/Institutes
  14. Papillary Thyroid Cancer - Companies Involved in Therapeutics Development
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Genzyme Corporation
  • Ignyta, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Plexxikon Inc.
  • Vaccinex, Inc.

For more information visit http://www.researchandmarkets.com/research/dvpgvs/papillary_thyroid